The European Alliance of Associations for Rheumatology (EULAR) has announced a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). Beginning in January 2025, the journal will be hosted on Elsevier’s premier online platform, ScienceDirect.
First published in 1939, Annals of the Rheumatic Diseases has consistently maintained its reputation for excellence in disseminating groundbreaking research and clinical insights in the field of rheumatology. The journal remains a leading publication in the discipline, featuring high-quality scientific papers, original research, reviews, recommendations, and viewpoints. It covers a broad spectrum of topics, including basic, clinical, and translational research across both inflammatory and non-inflammatory musculoskeletal conditions.
The journal’s success is due in large part to the dedication of its authors, reviewers, and editors, who volunteer their time and expertise to ensure the highest standards of scientific communication. Operating under a hybrid subscription-based model, ARD continues to make significant contributions to the global research community.
In 2023, Annals of the Rheumatic Diseases achieved an impressive Impact Factor of 20.3, ranking it second overall in the Rheumatology subject category and first among journals that publish original research advances. Additionally, the journal’s 2023 CiteScore of 35 places it in the 99th percentile (#1 out of 73) in the Medicine/Rheumatology category.
This new partnership with Elsevier marks a significant step for EULAR in ensuring that ARD remains at the forefront of rheumatology research and continues to be a vital resource for the international scientific community.
Click here to read the original press release.
